Lv4
490 积分 2024-07-10 加入
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
1个月前
已完结
Lecanemab in Early Alzheimer’s Disease
1个月前
已完结
Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease
1个月前
已完结
Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma
5个月前
已完结
First‐line immunotherapy combinations for recurrent or metastatic nasopharyngeal carcinoma: An updated network meta‐analysis and cost‐effectiveness analysis
5个月前
已完结
Cost-effectiveness of poly-(ADP-ribose) polymerase (PARP)-inhibitors for the maintenance treatment after responding to first- and second-line chemotherapy in advanced ovarian cancer
5个月前
已完结
Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma
5个月前
已完结
Cost–effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma
5个月前
已关闭
Cost-effectiveness of nivolumab in patients with NSCLC in the United States
5个月前
已完结
A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma
5个月前
已完结
皖公网安备34019202002308
